Why Wegovy May Pose Greater Vision Risks Than Expected

By VirentaNews Staff — May 23, 2026

Emerging evidence suggests that Wegovy, the high-profile weight-loss medication developed by Novo Nordisk, may be associated with a rare but serious risk of sudden vision loss due to a condition known as ‘eye stroke’—or non-arteritic anterior ischemic optic neuropathy (NAION). An analysis of over 20 million adverse event reports in the U.S. Food and Drug Administration’s (FDA) database found that the risk signal for NAION was nearly five times stronger among Wegovy users than among those taking Ozempic, another semaglutide-based drug. Despite both medications containing the same active ingredient, the disparity in risk profiles raises urgent questions about formulation, dosage, or patient factors that could amplify adverse outcomes, warranting updated clinical guidance and patient monitoring protocols.

Rare Vision Loss Signals in FDA Data

The study, conducted by researchers at the University of California, San Diego and published in JAMA Ophthalmology, analyzed adverse event reports submitted to the FDA Adverse Event Reporting System (FAERS) from 2017 to 2023. Among over 20 million entries, the team identified 88 cases of NAION linked to GLP-1 receptor agonists, with 45 specifically associated with Wegovy and 10 with Ozempic—despite Ozempic having a significantly larger user base. Using statistical signal detection methods, the researchers calculated a reporting odds ratio (ROR) of 4.8 for Wegovy compared to Ozempic, indicating a disproportionately higher number of NAION cases. NAION occurs when blood flow to the optic nerve is disrupted, leading to sudden, painless vision loss, typically in one eye. While rare, the condition is often irreversible, and prior case reports had already prompted the FDA to update labeling for semaglutide drugs in 2022 to include potential vision risks.

Key Players and Pharmaceutical Responses

Novo Nordisk, the Danish pharmaceutical giant behind both Wegovy and Ozempic, has maintained that the benefits of semaglutide outweigh the risks for most patients. In a public statement, the company acknowledged the JAMA study but emphasized that FAERS data cannot establish causation, noting that adverse event reports are unverified and subject to reporting bias. Nevertheless, Novo Nordisk has committed to further pharmacovigilance and is collaborating with regulatory agencies to assess the findings. Meanwhile, the FDA has not issued new restrictions but is reviewing the data as part of its ongoing safety monitoring. Ophthalmology associations, including the American Academy of Ophthalmology, have urged caution, recommending that patients on high-dose semaglutide therapies—particularly those with existing risk factors like sleep apnea, hypertension, or a history of optic nerve disorders—undergo baseline eye exams and report any visual disturbances immediately.

Trade-offs Between Weight Loss and Vision Risk

Wegovy, approved for chronic weight management, contains a higher dose of semaglutide (2.4 mg weekly) than Ozempic (up to 2.0 mg weekly), which is approved for type 2 diabetes but widely used off-label for weight loss. This dosage difference may partially explain the divergence in adverse event signals, as higher systemic exposure could influence vascular dynamics in sensitive tissues like the optic nerve. Additionally, rapid weight loss itself has been linked to changes in intracranial and ocular pressure, potentially compounding risk. On the other hand, Wegovy has demonstrated clinically significant outcomes: in the STEP clinical trials, patients lost an average of 15% of their body weight, with improvements in cardiovascular markers and diabetes risk. The challenge lies in balancing these substantial metabolic benefits against rare but devastating complications. For patients with obesity-related comorbidities, the drug may still represent a net positive, but informed consent must now include discussion of potential vision risks.

Why the Risk Signal Emerged Now

The heightened visibility of NAION risk associated with Wegovy is partly attributable to timing and scale. While semaglutide was introduced in 2017, its use for weight loss exploded after 2021, driven by celebrity endorsements, social media trends, and increased prescribing. As millions more patients began using Wegovy—especially at higher doses—the statistical power to detect rare adverse events improved. Additionally, greater awareness among clinicians and patients has likely increased reporting rates. The FDA’s 2022 label update, which first flagged potential NAION risk, also sensitized healthcare providers to monitor for symptoms. The current analysis benefits from a larger dataset and more refined detection algorithms, enabling researchers to distinguish between products that were previously grouped under the same pharmacological class, revealing previously obscured differences between formulations.

Where We Go From Here

In the next 6 to 12 months, three scenarios could unfold. First, regulatory agencies may require updated labeling for Wegovy with stronger warnings, including recommendations for pre-treatment ophthalmologic screening. Second, clinical guidelines could evolve to limit Wegovy’s use in patients with known risk factors for NAION, such as optic disc anatomy predisposing to crowding or untreated sleep apnea. Third, Novo Nordisk may initiate a prospective study to directly compare ocular safety outcomes between Wegovy and Ozempic users, potentially reshaping prescribing patterns. Each path hinges on whether the observed signal reflects biological differences in drug delivery, dosing, or patient selection—and whether future studies confirm a causal link. Until then, vigilance remains critical.

Bottom line — while Wegovy offers transformative benefits for obesity management, new evidence of a disproportionately higher risk of irreversible vision loss demands a recalibration of risk communication, patient screening, and long-term safety monitoring.

Source: ScienceDaily